Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY22 results · Jan–Mar 2022
Marksans Pharma reported revenue from operations of ₹418.04 crore (up 26.6% from Q4 FY21) and net profit of ₹29.65 crore (down 62.7% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 418.04 | 330.20 | +26.6% | 362.63 | +15.3% |
| Other income | 15.34 | 6.01 | +155.2% | 12.06 | +27.3% |
| Total income | 433.39 | 336.21 | +28.9% | 374.69 | +15.7% |
| Profit before tax | 52.60 | 97.22 | −45.9% | 60.35 | −12.8% |
| Net profit for the period | 29.65 | 79.50 | −62.7% | 48.27 | −38.6% |
| EPS, basic (₹) | 0.69 | 1.93 | −64.2% | 1.20 | −42.5% |
| Net margin (%) | 7.1 | 24.1 | 13.3 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 176.28 | 137.58 | +28.1% | 165.94 | +6.2% |
| Other income | 7.65 | 11.91 | −35.8% | 12.06 | −36.6% |
| Total income | 183.93 | 149.49 | +23.0% | 178.00 | +3.3% |
| Profit before tax | 28.63 | 32.40 | −11.6% | 34.68 | −17.4% |
| Net profit for the period | 21.43 | 23.69 | −9.5% | 26.06 | −17.8% |
| EPS, basic (₹) | 0.52 | 0.58 | −10.3% | 0.64 | −18.8% |
| Net margin (%) | 12.2 | 17.2 | 15.7 |
Consolidated
- Filed with BSE
- 31 May 2022, 17:58 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 May 2022, 17:58 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE